OncoStem launches hospital-based breast cancer risk testing kit

OncoStem Therapeutics is introducing a hospital-use diagnostic kit designed to bring breast cancer risk testing closer to patients, addressing longstanding barriers to accessing personalised treatment guidance. The decentralised testing approach eliminates the need to send samples to centralised laboratories, streamlining the diagnostic process and reducing turnaround times for results.

The company anticipates that the new kit will double annual testing volumes as it becomes more accessible to hospitals and diagnostic centres across India. By enabling in-house testing capabilities, the solution addresses infrastructure challenges that have previously limited uptake of genetic risk assessments in smaller healthcare facilities.

Breast cancer risk stratification helps clinicians identify individuals carrying genetic mutations or other markers associated with elevated disease susceptibility, enabling early intervention and tailored prevention strategies. The ability to conduct these tests at the hospital level is expected to facilitate wider adoption of personalised oncology practices, particularly in tier-two and tier-three cities where centralised laboratory access remains constrained.

The initiative reflects growing momentum in India's diagnostic sector toward decentralised healthcare solutions that bring advanced testing capabilities beyond major metropolitan centres. For OncoStem, the expansion represents a significant opportunity to establish its technology across India's fragmented healthcare landscape while supporting the country's broader push toward precision medicine.